In multiple syngeneic tumour models, a single low dose (0.5–1.25 μg) of CDN-conjugated nanoparticles, in combination with checkpoint blockade, resulted in 60–100% tumour rejection and robust immune memory upon rechallenge. Here, NT5C is linked to neoplasm.